AIDS 2024 Pharmacist LA ART
Integrating New Data From AIDS 2024: Pharmacist Perspectives

Released: September 04, 2024

Expiration: September 03, 2025

Jennifer Cocohoba
Jennifer Cocohoba, PharmD, AAHIVP
David Koren
David Koren, PharmD, MPH, AAHIVP, FIDSA
Nimish Patel
Nimish Patel, PharmD, PhD, AAHIVP

Activity

Progress
1
Course Completed

In this episode, Jennifer Cocohoba, PharmD, AAHIVP, and David Koren, PharmD, MPH, AAHIVP, FIDSA, cover the most impactful LA ART and LA PrEP clinical studies presented at AIDS 2024, including:

  • The PURPOSE 1 study of twice-yearly lenacapavir injections vs daily oral tenofovir as PrEP in cisgender women
  • An open-label extension of HPTN 084 evaluating LA CAB safety during pregnancy
  • 48-week data from the IMPAACT 2017/MOCHA study of LA CAB + RPV in adolescents with HIV
  • A substudy of FLAIR evaluating the efficacy, safety, and tolerability of SC self-administration of LA CAB + RPV